RecruitingNot ApplicableNCT07553247

Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children

Evaluation of the Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children


Sponsor

Zagazig University

Enrollment

54 participants

Start Date

Jun 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Preschool children have specific anatomical and physiological characteristics which necessitates careful selection of an appropriate airway management device. Supraglottic airway devices can be used in anticipated or unanticipated difficult airway providing continuous oxygenation and ventilation with less hemodynamic stress response and less postoperative complications. So alternative techniques such as SADs have gained prominence in pediatric anesthesia both as primary airway and as a conduit for endotracheal intubation. So this study will evaluate the clinical performance of Laryseal Clear and Ambu Aura40 laryngeal mask airway in preschool children undergoing surgical procedures.


Eligibility

Min Age: 3 YearsMax Age: 6 Years

Inclusion Criteria5

  • Consent of patient's parents or guardians of the first degree.
  • American Society of Anesthesiologists (ASA) Class I or II.
  • BMI: 5-85% of the children of the same age and sex.
  • Patients with mallampati grade I, II
  • Type of anesthesia: general anesthesia expected to last for less than 2 hours.

Exclusion Criteria6

  • Emergency surgeries.
  • Expected difficult airway.
  • Patients with congenital or acquired airway malformations.
  • Patients with active upper respiratory tract infection at the time of surgery.
  • Patients with history of gastroesophageal reflux disease (GERD).
  • Patients with neuromuscular disorders affecting airway tone or respiratory function.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELarySeal clear Group

Patient's airway will be secured with the LarySeal laryngeal mask. Selection of the LMA size will be based on the body weight of the patient (Bennett et al., 1996). The device will be lubricated by a water-based jelly before placement. The head of the patient will be placed in the dorsiflexion sniffing position and a lubricated LMA of appropriate size (LarySeal, Flexicare medical Ltd., UK) will be inserted using the index finger digital method technique according to manufacturers guideline. To ensure optimal inflation of SGAD cuff, it will be inflated with a volume of air according to the manufacturer's guidance (7 ml for size 1.5, 10 ml for size 2, 14 ml for size 2.5, and 20 ml for size 3).

DEVICEAmbu Aura40 Group

Patient's airway will be secured with the Ambu Aura40 laryngeal mask.Selection of the LMA size will be based on the body weight of the patient. The device will be lubricated by a water-based jelly before placement. Patient's head will be in neutral position, a lubricated Ambu® Aura40(Ambu A/S, Copenhagen, Denmark) of appropriate size will be inserted using the non rotational midline approach according to manufacturer's guideline. To ensure optimal inflation of SGAD cuff, it will be inflated with a volume of air according to the manufacturer's guidance (7 ml for size 1.5, 10 ml for size 2, 14 ml for size 2.5, and 20 ml for size 3).


Locations(1)

Zagazig university hospitals

Zagazig, Sharqia Province, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07553247